STEKStemtech Corp.

About Stemtech Corp. (STEK)

Stemtech Corp. (STEK) is a Drug Manufacturers - Specialty & Generic company headquartered in Naples, FL, United States whose shares trade over-the-counter on the OTCQB tier.

Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB: STEK) and has expanded business opportunities for its Independent Business Partners, who may earn incomes by sharing Stemtech products. In September 2022, the new Stemtech AdvanceOffice mobile app was successfully launched as a powerful communication – recruiting tool for our Field. Stemtech offers our all-natural, plant-based RCM - stemrelease3™ (release), StemFlo® (Circulate) and MigraStem® (migration) nutritional supplement products, in addition to OraStem®, an all-natural toothpaste and StemPets™. In January 2023, Stemtech launched leading-edge proprietary blend, FDA approved ingredient, Cellect One® Rapid Renew Stem Cell Peptide Night Cream skincare product. In January 2025, Cellect One® Shield: HOCL (Hypochlorous Acid) Mist skin care and disinfectant was introduced.

Products and services

Stemtech offers our all-natural, plant-based RCM - release, circulate and migration nutritional (stemceutical™) supplement products, in addition to OraStem®, an all-natural toothpaste. In January 2023, Stemtech launched leading-edge proprietary blend, FDA approved ingredient, Cellect One® Rapid Renew Stem Cell Peptide Night Cream skincare product. .

STEK key facts

Ticker symbol

STEK

Market tier

OTCQB

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Naples, FL, United States

Country of incorporation

US

Year of incorporation

2009

Employees

31

Estimated market cap

$4.27M (as of Apr 10, 2025)

Shares outstanding

142,443,444

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Stemtech Corp. leadership

• Charles S. Arnold — CEO
• John W. Meyer — President, COO
• James Shelton Cardwell — CFO
• David E. Price — Corporate Secretary
• Srilakshmi Vadlapatla — Accountant
• Accounts Payable — Other

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with S